<?xml version='1.0' encoding='utf-8'?>
<document id="20701552"><sentence text="Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies."><entity charOffset="0-11" id="DDI-PubMed.20701552.s1.e0" text="Raltegravir" /></sentence><sentence text="Raltegravir is the first HIV-integrase inhibitor licensed by the FDA"><entity charOffset="0-11" id="DDI-PubMed.20701552.s2.e0" text="Raltegravir" /></sentence><sentence text="" /><sentence text="A PubMed search was conducted for all published reports up to 1 May 2010 related to raltegravir pharmacokinetics, pharmacology, drug-drug interactions and clinical studies in HIV-infected patients" /><sentence text=" Also included in this review are the updated European and US Prescriber's Information (European Medicines Agency and the FDA) and abstracts from recent international scientific meetings" /><sentence text="" /><sentence text="After reading the review, a thorough insight in raltegravir pharmacokinetics and pharmacology will be obtained, as well as an up-to-date overview of all published drug-drug interaction studies" /><sentence text=" Furthermore, one should be able to make an evidence-based opinion on the drug's clinical efficacy and tolerability" /><sentence text="" /><sentence text="Raltegravir is a welcome addition to the antiretroviral drug armamentarium due to its good tolerability, low potential for drug-drug interactions and good clinical efficacy in both treatment-naive and -experienced patients"><entity charOffset="0-11" id="DDI-PubMed.20701552.s10.e0" text="Raltegravir" /></sentence><sentence text="" /></document>